INSIGHT INTO PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS AND THERAPEUTIC ROLE OF GLP-1 AND SGLT INHIBITORS: A SYSTEMATIC REVIEW

Authors

  • Muhammad Uzair Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author
  • Nabiha Khursheed Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan. Author
  • Abeera Nasir Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan. Author
  • Muskan Saleem Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author
  • Abdul Ahad Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author
  • Zainab Ali Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author
  • Aiman Noreen Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author
  • Muhammad Sulaiman Saeed Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan Author

DOI:

https://doi.org/10.71000/mph7kz17

Keywords:

GLP-1 agonists, , Insulin resistance, Cardiovascular protection, GLP-1 receptor agonists, Renal outcomes, SGLT2 inhibitors, T2DM pathophysiology, Weight reduction

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder marked by insulin resistance, β-cell dysfunction, and progressive organ damage. The global burden of T2DM continues to rise, with over 537 million individuals affected as of 2021. Given the limitations of traditional antidiabetic therapies, there is an urgent need to explore newer agents that target underlying pathophysiological mechanisms and offer additional organ-protective benefits.

Objective: To systematically evaluate the pathophysiological mechanisms of T2DM and assess the clinical effectiveness and safety of GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 (SGLT2) inhibitors in its management.

Methods: A systematic review was conducted using PubMed and Google Scholar databases to retrieve relevant literature published from 2015 to 2025. A total of 143 articles were initially identified using keywords such as "GLP-1 receptor agonist," "SGLT2 inhibitor," and "T2DM pathophysiology." After applying inclusion and exclusion criteria, 42 full-text articles were selected for detailed analysis. Studies included randomized controlled trials, cohort studies, and meta-analyses evaluating therapeutic outcomes of GLP-1 RAs and SGLT2 inhibitors in adult T2DM patients.

Results: GLP-1 RAs demonstrated an average HbA1c reduction of 0.8% to 1.8% and body weight reduction of 2.5 to 6.5 kg. Tirzepatide outperformed semaglutide with an additional 6.56 kg mean weight loss. SGLT2 inhibitors lowered HbA1c by 0.5% to 1.0%, reduced systolic blood pressure by 3–6 mmHg, and body weight by 2–3 kg. Both drug classes showed significant cardiovascular and renal protective effects in patients with established comorbidities. Combination therapy further improved glycemic outcomes without increasing hypoglycemia risk.

Conclusion: GLP-1 RAs and SGLT2 inhibitors offer multifaceted benefits in T2DM by addressing core metabolic dysfunctions and reducing long-term complications. Their integration into clinical practice supports a more personalized and organ-protective approach to diabetes care.

Author Biographies

  • Muhammad Uzair, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Nabiha Khursheed, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan.

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Abeera Nasir, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan.

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Muskan Saleem, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Abdul Ahad, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Zainab Ali, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Aiman Noreen, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

  • Muhammad Sulaiman Saeed, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

    Institute of Health Sciences, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan

References

Baars, D. P., Fondevila, M. F., Meijnikman, A. S., & Nieuwdorp, M. (2024). The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes. Cell Host and Microbe, 32(8), 1280–1300.

Basak, M., & Laskar, M. A. (2024). COMPLICATIONS OF TYPE-2 DIABETES: A REVIEW. 12(3), 1–10.

Brunton, S. A., & Wysham, C. H. (2020). GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine, 132(sup2), 3–14.

Caruso, I., Di Gioia, L., Di Molfetta, S., Cignarelli, A., Palmer, S. C., Natale, P., Strippoli, G. F. M., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2023). Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine, 64, 102181.

Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology, 8(January).

Cornell, S. (2020). A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. Journal of Clinical Pharmacy and Therapeutics, 45(S1), 17–27.

Dalsgaard, E. M., Skriver, M. V., Sandbaek, A., & Vestergaard, M. (2015). Socioeconomic position, type 2 diabetes and long-term risk of death. PLoS ONE, 10(5), 1–10.

Fex, M., Nicholas, L. M., Vishnu, N., Medina, A., Sharoyko, V. V., Nicholls, D. G., Spégel, P., & Mulder, H. (2018). The pathogenetic role of β-cell mitochondria in type 2 diabetes. Journal of Endocrinology, 236(3), R145–R149.

Fioretto, P., Zambon, A., Rossato, M., Busetto, L., & Vettor, R. (2016). SGLT2 inhibitors and the diabetic kidney. Diabetes Care, 39(August), S165–S171.

Galicia-garcia, U., Benito-vicente, A., Jebari, S., & Larrea-sebal, A. (2020). Costus ignus: Insulin plant and it’s preparations as remedial approach for diabetes mellitus. International Journal of Molecular Sciences, 1–34.

Joshi, N., Baloch, K. M., Rukh, S., & Khan, A. M. (2024). Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review. 0(July), 7255–7264.

Lee, S. H., Park, S. Y., & Choi, C. S. (2022). Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes and Metabolism Journal, 46(1), 15–37.

Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017). Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care, 40(4), 614–624.

Mashima, H., Zhang, R., Kobayashi, T., Hagiya, Y., Tsukamoto, H., Liu, T., Iwama, T., Yamamoto, M., Lin, C., Nakatsuka, R., Mishima, Y., Watanabe, N., Yamada, T., Senju, S., Kaneko, S., Idiris, A., Nakatsura, T., Ohdan, H., & Uemura, Y. (2020). Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. OncoImmunology, 9(1).

Olaogun, I., Farag, M., & Hamid, P. (2020). The Pathophysiology of Type 2 Diabetes Mellitus in Non-obese Individuals: An Overview of the Current Understanding. Cureus, 12(4), 2–6.

Qasim, S. F., Ahsan, T., Ghaus, S., & Imran, P. (2023). Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi. Pakistan Journal of Medical Sciences, 39(4).

Reed, J., Bain, S., & Kanamarlapudi, V. (2021). A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes, Metabolic Syndrome and Obesity, 14, 3567–3602.

Santos, L. L., De Lima, F. J. C., De Sousa-Rodrigues, C. F., & Barbosa, F. T. (2017). Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Revista Da Associacao Medica Brasileira, 63(7), 636–641.

Simes, B. C., & Mac Gregor, G. G. (2019). Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and Obesity, 12, 2125–2136.

Valaiyapathi, B., Gower, B., & Ashraf, A. P. (2019). Pathophysiology of Type 2 Diabetes in Children and Adolescents. Current Diabetes Reviews, 16(3), 220–229.

Verma, S., & McMurray, J. J. V. (2018). (KALP RESMİ OLAN) SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review (KALP RESMİ OLAN). Diabetologia, 61(10), 2108–2117.

Won, H., Cho, J. Y., & Lee, S. (2025). Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials. Translational and Clinical Pharmacology, 33(1), 1–9.

Wright, E. M. (2021). SGLT2 Inhibitors: Physiology and Pharmacology. Kidney360, 2(12), 2027–2037.

Xu, G., Xu, S., Shi, X., Shen, C., Hao, J., Yan, M., Zhang, D., Zhu, Z., Zhang, K., Zheng, H., & Liu, X. (2020). Intercellular transmission of Seneca Valley virus mediated by exosomes. Veterinary Research, 51(1), 1–10.

Downloads

Published

2025-06-16

Issue

Vol. 3 No. 3 (Health & Rehabilitation) (2025): Volume 3 Issue 3 2025

Section

Articles

License

Copyright (c) 2025 Muhammad Uzair, Nabiha Khursheed, Abeera Nasir, Muskan Saleem, Abdul Ahad, Zainab Ali, Aiman Noreen, Muhammad Sulaiman Saeed (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.